Can We Disable Autoimmunity Without Disabling the Immune System?
Mapping the STAT4–IRF5–NF-kB Patho-enhanceosome at Autoimmune Super-Enhancers and Evaluating SLC15A4–TASL Disruption for Disease-Selective Immunosuppression
Synthesized from 40M+ biomedical papers using BioSkepsis an AI research platform for evidence-grounded scientific discovery. This proposal links to its full interactive study with source-level traceability.
Rationale
Autoimmune risk variants overwhelmingly reside in non-coding enhancers rather than protein-coding genes, with approximately 60% of likely causal variants for 21 autoimmune diseases mapping to stimulus-dependent CD4+ T-cell enhancers enriched for NF-kB, PU.1, IRF4, and BATF binding sites. STAT4, IRF5, and NF-kB rarely operate in isolation: roughly 74% of primary immune response genes are governed by combinatorial transcription factor logics (AND-gate and OR-gate). IRF5 and NF-kB p50 form a unique synergistic cistrome at pro-inflammatory cytokine promoters, while STAT4 and IRF5 risk variants exhibit additive effects on SLE susceptibility, suggesting convergence on shared enhancer targets. The recent identification of TASL (encoded by CXorf21) as the specific innate immune adaptor required for TLR7/9-mediated IRF5 activation—but dispensable for cytoplasmic RIG-I/STING sensing—opens a pathway-selective intervention point. Whether these three factors physically co-occupy disease-associated super-enhancers as a heteromeric ‘patho-enhanceosome,’ and whether disrupting TASL-mediated IRF5 recruitment can dismantle this complex without pan-immunosuppression, remains untested.
Proposed Approach
Primary monocytes and CD4+ T cells will be isolated from SLE patients stratified by STAT4 rs7574865 and IRF5 genotype. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) for STAT4, IRF5, and NF-kB (p65/p50) will map co-occupancy at genome-wide enhancers, with Hi-ChIP used to identify active enhancer–promoter loops at loci including TNF, IL6, and IL2RA. Cells will be perturbed with TASL-selective small-molecule inhibitors (e.g., feeblin) or siRNA-mediated knockdown of SLC15A4/TASL. Primary readouts include ChIP-binding occupancy shifts at super-enhancers, nascent RNA expression via chromatin-associated RNA-seq (caRNA-seq) for core inflammatory cytokines, and differential pathway activation comparing endosomal TLR7 stimulation (TASL-dependent) versus cytoplasmic RIG-I/STING activation (TASL-independent). Healthy donors carrying matched risk variants will serve as controls to distinguish baseline genetic effects from active disease-induced chromatin states.
Expected Impact
If the STAT4–IRF5–NF-kB patho-enhanceosome is confirmed, it redefines autoimmune risk enhancers as precision drug targets rather than broad immunosuppressive loci. Validating TASL disruption as a disease-selective strategy would open a new therapeutic class that silences endosomal-derived pathogenic signals while preserving cytoplasmic antiviral defenses directly addressing the long-standing clinical conflict between controlling autoimmunity and maintaining host immunity. This genotype-stratified approach also advances precision medicine by linking specific risk allele combinations to tailored intervention strategies.
Testable Hypothesis
The pathogenic over-activation of pro-inflammatory cytokines in systemic lupus erythematosus is driven by the formation of a STAT4–IRF5–NF-kB ‘patho-enhanceosome’ on disease-associated super-enhancers, nucleated by the STAT4 rs7574865 risk allele and stabilized by TASL-mediated recruitment of IRF5. Selective disruption of the SLC15A4–TASL interaction will dismantle this complex and produce disease-selective immunosuppression reducing TLR7/9-driven cytokine expression while leaving RIG-I/STING-mediated antiviral responses intact.
How This Proposal Was Generated
This proposal was derived through systematic literature synthesis on the BioSkepsis platform (app.bioskepsis.ai). The process involved:
Semantic search across 40M+ curated biomedical papers using biology-native retrieval (Gene Ontology terms, MeSH descriptors, gene names, domain-specific embeddings).
Full-text analysis of retrieved publications not just abstracts, including methods, supplementary data, and discussion sections where knowledge gaps are typically identified.
Mechanistic link extraction structured tables mapping molecular factor ® link type ® target ® effect, grounded in specific publications with confidence scores.
Research landscape synthesis tracing how the evidence base evolved across phases, identifying hub pathways, bridge domains, replication ratios, and methodological biases.
Hypothesis generation with empirically testable predictions, proposed study designs, explicit confounders, and risk/limitation assessments, all traceable to source passages.
Cross-domain synthesis to surface connections invisible within single-discipline searches.
BioSkepsis is free for individual researchers. This proposal links directly to the full interactive study where you can explore citation networks, mechanistic tables, and extend the analysis with your own questions.
Selected References
References that informed this proposal. Full citation networks and source-level traceability are available within the linked BioSkepsis study.
[1] Drobek A, Bernaleau L, Delacrétaz M, et al. The TLR7/9 adaptors TASL and TASL2 mediate IRF5-dependent antiviral responses and autoimmunity in mouse. Nature Communications. 2025;16. PMID: 39856058.
[2] Wang N, Lefaudeux D, Mazumder A, Li J, Hoffmann A. Identifying the combinatorial control of signal-dependent transcription factors. PLoS Computational Biology. 2021;17. PMID: 34166361.
[3] Nica V, Gaal O, Badii M, et al. Gout Risk Allele Regulating IRF5 Expression Is Associated with Enhanced IL-1b Production in Response to Palmitate and Monosodium Urate Crystals. Int J Mol Sci. 2025;26. PMID: 41155224.
[4] Hagberg N, Joelsson M, Leonard D, et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-g production in T cells from patients with SLE. Ann Rheum Dis. 2018. PMID: 29475858.
[5] Frömel R, Rühle J, Martinez AB, et al. Design principles of cell-state-specific enhancers in hematopoiesis. Cell. 2025;188:3202–3218.e21. PMID: 40345201.
[6] Farh K, Marson A, Zhu J, et al. Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants. Nature. 2014;518:337–343. PMID: 25363779.
[7] Hnisz D, Abraham B, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013. PMID: 24119843.
[8] Zhang Y, Zou Z, Li R, et al. DTX1 Modulates Microglial M1 Polarization and Exacerbates Neuroinflammation in Traumatic Brain Injury Model Rats through NF-kB/IRF5. Mol Neurobiol. 2025;62:14140–14155. PMID: 40660011.
[9] Shao Q, Wang H, Li S, et al. IRF5 Mediates Artery Inflammation in Salt-Sensitive Hypertension by Regulating STAT1 and STAT2 Phosphorylation to Increase ESM1 Transcription. Int J Mol Sci. 2025;26. PMID: 40332339.
[10] Newby B, Brusko T, Zou B, et al. Type 1 Interferons Potentiate Human CD8+ T-Cell Cytotoxicity Through a STAT4- and Granzyme B–Dependent Pathway. Diabetes. 2017;66:3061–3071. PMID: 28877912.
[11] Alakhras NS, Zhang W, Barros N, et al. An IL-23-STAT4 pathway is required for the proinflammatory function of classical dendritic cells during CNS inflammation. PNAS. 2024;121. PMID: 39088391.
[12] Afzali B, Grönholm J, Vandrovcova J, et al. BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nat Immunol. 2017;18:813–823. PMID: 28530713.
[13] Gao P, Uzun Y, He B, et al. Risk variants disrupting enhancers of TH1 and TREG cells in type 1 diabetes. PNAS. 2019;116:7581–7590. PMID: 30910956.
[14] Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Molecular Cell. 2010. PMID: 20513432.
[15] Tanaka Y, Luo Y, O’Shea J, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133–145. PMID: 34987201.
[16] Saevarsdottir S, Stefánsdóttir L, Sulem P, et al. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Ann Rheum Dis. 2022;81:1085–1095. PMID: 35470158.
[17] Matta B, Thomas L, Sharma V, Barnes BJ. Dysregulation of T Follicular Helper and Regulatory Cells in IRF5-SLE Homozygous Risk Carriers and Systemic Lupus Erythematosus Patients. Cells. 2025;14. PMID: 40136703.